Adoptive cell transfer (ACT) therapy—including CAR T-Cell Therapy and tumor-infiltrating lymphocyte (TIL) therapy—has produced dramatic responses in some cancers, but success remains limited in solid tumors. The primary barrier is the Tumor Microenvironment Modulation needed to overcome the immunosuppressive conditions that prevent transferred